IFW Reference Manager

Application Number: [ ] Submit

Application Number 10/735,607

Testing 605416 - Form PTO-1449, 19-APR-2004, Paper Number 20040419

Document Number	Date	Inventor Names	Classification
US-5,064,833	11-1991	Ife et al.	514/266.4
US-5,420,135	05-1995	Brown et al.	514/293
US-5,814,630	09-1998	Barker et al.	514/234.5
US-5,939,421	08-1999	Palanki et al.	514/266.2
US-6,169,091	01-2001	Cockerill et al.	514/228.2
US-6,174,889	01-2001	Cockerill et al.	514/264.1
US-6,207,669	03-2001	Cockerill et al.	514/264.1
US-6,225,318	05-2001	Sobolov-Jaynes et al.	514/266.2
US-6,248,771	06-2001	Shenoy et al.	514/418
US-6,251,912	06-2001	Wissner et al.	514/228.2
US-6,391,874	05-2002	Cockerill et al.	514/233.5
US-6,395,733	05-2002	Arnold et al.	514/234.2
US-6,399,602	06-2002	Barker et al.	514/234.5
US-6,413,971	07-2002	Arnold et al.	514/264.11

EAST Search String:

("5064833"|"5420135"|"5814630"|"5939421"|"6169091"|"6174889"|"6207669"|"6225318"|"6248771"|"6

10/ 735,607

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 05	CASREACT(R) - Over 10 million reactions available
NEWS 4	DEC 14	2006 MeSH terms loaded in MEDLINE/LMEDLINE
NEWS 5	DEC 14	2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
NEWS 6	DEC 14	CA/CAplus to be enhanced with updated IPC codes
NEWS 7	DEC 21	IPC search and display fields enhanced in CA/CAplus with the IPC reform
NEWS 8	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 9	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 10	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 11	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 12	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 13	JAN 30	Saved answer limit increased
NEWS 14	JAN 31	Monthly current-awareness alert (SDI) frequency added to TULSA

NEWS EXPRESS	JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:56:15 ON 07 FEB 2006

=> FIL STNGUIDE

10/ 735,607

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 13:56:22 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Feb 3, 2006 (20060203/UP).

=> FIL HOME

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	0.27

FILE 'HOME' ENTERED AT 13:56:27 ON 07 FEB 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.48

FILE 'REGISTRY' ENTERED AT 13:56:34 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5
DICTIONARY FILE UPDATES: 6 FEB 2006 HIGHEST RN 873652-66-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

10/ 735,607

=>
Uploading C:\Program Files\Stnexp\Queries\10735607.str





chain nodes :
11 12 18
ring nodes :
1 2 3 4 5 6 7 8 9 10
ring/chain nodes :
13 14
chain bonds :
2-18 7-11 9-13 11-12 13-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
exact/norm bonds :
2-18 7-11 11-12 13-14
exact bonds :
9-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10
isolated ring systems :
containing 1 :

G1:C,H,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:CLASS 14:CLASS 18:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,H,O,S,N

Structure attributes must be viewed using STN Express query preparation.

10/ 735,607

```
=> s l1 sample
SAMPLE SEARCH INITIATED 13:56:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        3 TO ITERATE

100.0% PROCESSED         3 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            3 TO      163
PROJECTED ANSWERS:               3 TO      163

L2             3 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 13:57:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       71 TO ITERATE

100.0% PROCESSED        71 ITERATIONS                                61 ANSWERS
SEARCH TIME: 00.00.01

L3            61 SEA SSS FUL L1

=> file hcaplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   167.38     167.86

FILE 'HCAPLUS' ENTERED AT 13:57:28 ON 07 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006  VOL 144 ISS 7
FILE LAST UPDATED: 6 Feb 2006  (20060206/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d his

     (FILE 'HOME' ENTERED AT 13:56:15 ON 07 FEB 2006)

     FILE 'STNGUIDE' ENTERED AT 13:56:22 ON 07 FEB 2006

     FILE 'HOME' ENTERED AT 13:56:27 ON 07 FEB 2006

     FILE 'REGISTRY' ENTERED AT 13:56:34 ON 07 FEB 2006
```

10/ 735,607

L1 STRUCTURE UPLOADED
L2 3 S L1 SAMPLE
L3 61 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 13:57:28 ON 07 FEB 2006

=> s l3
L4 4 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:238986 HCAPLUS
DOCUMENT NUMBER: 142:316855
TITLE: Substituted bicyclic quinazolin-4-ylamine derivatives as capsaicin receptor modulators
INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Chenard, Bertrand L.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 109 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023807	A2	20050317	WO 2004-US29583	20040909
WO 2005023807	A3	20050421		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2003-501515P P 20030909
US 2003-515984P P 20031031
OTHER SOURCE(S): MARPAT 142:316855
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein B, V, X, Y, W, Z = independently N, CR1, such that at least one of V and X is N; D = N, CR9; either EF forms an (un)substituted fused 5- to 7-membered carbocylyl, or heterocyclyl; and A = N, CR1 with proviso; or AF forms an (un)substituted fused 5- to 7-membered carbocylyl, or heterocyclyl; and E = N, CR9; each R1 = independently H, halo, OH, CN, NH2, NO2, CO2H and derivs., etc.; each R9 = independently H, halo, OH, CN, alkylsulfonyl, alkylsulfonamido, etc.; U = N, CR2, with the proviso that if V and X are both N, then U = CR2; R2 = H, halo, CN, CO2H, etc.; Ar = (un)substituted 5- to 10-membered aromatic carbocycles or heterocycles, such that Ar is not thiophene; and their pharmaceutically acceptable salts], useful for treating conditions related to capsaicin receptor activation, were prepared I modulate, preferably inhibit binding of vanilloid ligand to VR1 activation capsaicin receptor VR1 (vanilloid receptor subtype 1), exhibit no detectable agonist activity in an in vitro assay of capsaicin receptor agonism, show IC50 of ≤1 μM in a capsaicin receptor calcium mobilization assay, and reduce calcium conductance of a cellular capsaicin receptor. Radiolabeled

L4 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
compds. I are used for detg. the presence or absence of capsaicin receptor in a sample in receptor localization studies. A 7-step synthesis is given for title compd. II·HCl (no data for the intermediates).
IT 848046-95-7P, [7-(3-Chloropyridin-2-yl)-2-[(2,6-dimethylmorpholin-4-yl)methyl]pyrido[2,3-d]pyrimidin-4-yl](2,4,4-trimethyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of bicyclic quinazolin-4-ylamine derivs. as type VR1 capsaicin receptor modulators)
RN 848046-95-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 7-(3-chloro-2-pyridinyl)-2-[(2,6-dimethyl-4-morpholinyl)methyl]-N-(1,2,3,4-tetrahydro-2,4,4-trimethyl-7-isoquinolinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534192 HCAPLUS
DOCUMENT NUMBER: 141:89101
TITLE: Preparation of carboxylic acid, phosphate, or phosphonate substituted (quinazolin-4-yl)amines as capsaicin receptor modulators
INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Caldwell, Timothy M.; De Lombaert, Stephane; Hodgetts, Kevin J.; Zheng, Xiaozhang
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055004	A1	20040701	WO 2003-US39607	20031212
WO 2004055004	C1	20050721		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2509239	AA	20040701	CA 2003-2509239	20031212
US 2004156869	A1	20040812	US 2003-735607	20031212
EP 1569926	A1	20050907	EP 2003-813411	20031212

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.: US 2002-433139P P 20021213
WO 2003-US39607 W 20031212
OTHER SOURCE(S): MARPAT 141:89101
GI

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Title acid-substituted (quinazolin-4-yl)amines and analogs (I) [wherein V, W, X, Y, and Z = independently N, CR1, with the proviso that at least one of V and X = N; U = N, CR2, with the proviso that if V and X = N, then U = CR2; R1 = independently H, halo, OH, CN, NH2, CO2H, (halo)alkyl, (halo)alkoxy, alkoxycarbonyl, (di)alkylamino; R2 = H, halo, CN, NO2, (un)substituted alkyl, alkenyl, or alkynyl optionally interrupted by O, S, SO, SO2, CO, OCO, CO2, OCO2, CHNH, NHCO, NHSO2, SO2NH, NH, OPO2(OH), or PO2(OH); Ar1 and Ar2 = independently (un)substituted carbocyclyl, heterocyclyl; and pharmaceutically acceptable forms thereof] were prepared as modulators of capsaicin receptors, especially the vanilloid receptor 1 (VR1).
For example, 2-tert-butyl-5-nitrophenol was condensed with 2-(tert-butyldimethylsilyloxy)ethanol, and the resulting nitrophenyl ether reduced to give the substituted aniline. Condensation of the phenylamine with 4-chloro-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-ol, followed by deprotection, coupling with L-proline Me ester, and saponification provided II.
In competition binding assays, invention compds. exhibited Ki ≤ 1 μM for VR1 expressed in human embryonic kidney (HEK293) cells. Thus, I and their pharmaceutical compns. are useful for treating disorders associated with pathol. receptor activation, such as pain, in humans, domesticated companion animals, and livestock animals (no data).
IT 714223-61-7P 714223-63-9P 714223-64-0P
714223-72-0P 714223-73-1P 714223-74-2P
714223-75-3P 714223-76-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(VR1 inhibitor; preparation of acid-substituted (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)
RN 714223-61-7 HCAPLUS
CN L-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 714223-63-9 HCAPLUS
CN L-Proline, 1-[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714223-64-0 HCAPLUS
CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-74-2 HCAPLUS
CN Butanoic acid, 4-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 714223-75-3 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-72-0 HCAPLUS
CN Glycine, N-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-73-1 HCAPLUS
CN β-Alanine, N-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 714223-76-4 HCAPLUS
CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:534191 HCAPLUS
DOCUMENT NUMBER: 141:89100
TITLE: Preparation of (quinazolin-4-yl)amines as capsaicin receptor modulators
INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Brielmann, Harry; Caldwell, Timothy M.; De Lombaert, Stephane; Hodgetts, Kevin J.; Zheng, Xiaozhang
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 226 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055003	A1	20040701	WO 2003-US39606	20031212
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2509233	AA	20040701	CA 2003-2509233	20031212
US 2004156869	A1	20040812	US 2003-735607	20031212
EP 1569925	A1	20050907	EP 2003-813410	20031212
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017168	A	20051101	BR 2003-17168	20031212
PRIORITY APPLN. INFO.:			US 2002-433139P P	20021213
			WO 2003-US39606 W	20031212

OTHER SOURCE(S): MARPAT 141:89100
GI


I


II

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
AB Title compds. I [wherein V, W, X, Y, and Z = independently N, CR1, with the proviso that at least one of V and X = N; R = OR7, NR3R4; R1 = independently H, halo, OH, CN, NH2, (halo)alkyl, (halo)alkoxy, alkoxycarbonyl, (di)alkylamino; R3 and R4 = independently H, (un)substituted (aryl)alkyl, alkenyl, alkynyl, alkanoyl, etc.; or R3 or R4 taken together with R5 or R6 forms an (un)substituted heterocycle; or NR3R4 = heterocyclyl; R5 and R6 = independently H, (un)substituted alkyl; or CR5R6 = CO; R7 = H, (aryl)alkyl, alkenyl, alkynyl, alkanoyl, etc.; or R7 taken together with R5 or R6 forms an (un)substituted heterocycle; n = 1-3; Ar1 and Ar2 = independently (un)substituted aryl, heterocyclyl; and pharmaceutically acceptable forms thereof] were prepared as modulators of capsaicin receptors, especially the vanilloid receptor 1 (VR1). For example, a solution of [2-(chloromethyl)-7-(3-trifluoromethylpyridin-2-yl)quinazolin-4-yl](4-trifluoromethylphenyl)amine•HCl and pyrrolidine was heated to 100° for 1 h to give II. In competition binding assays, invention compds. exhibited Ki ≤ 1 μM for VR1 expressed in human embryonic kidney (HEK293) cells. Thus, I and their pharmaceutical compns. are useful for treating disorders associated with pathol. receptor activation, such as pain, in humans, domesticated companion animals, and livestock animals (no data).
IT **573688-59-2P 573688-81-0P 573688-83-2P**
573688-84-3P 573688-88-7P 573688-89-8P
714222-76-1P 714222-78-3P 714222-80-7P
714222-82-9P 714222-84-1P 714222-86-3P
714222-88-5P 714222-89-6P 714222-90-9P
714222-91-0P 714222-92-1P 714222-93-2P
714222-94-3P 714222-95-4P 714222-96-5P
714222-97-6P 714222-98-7P 714222-99-8P
714223-00-4P 714223-01-5P 714223-02-6P
714223-03-7P 714223-04-8P 714223-05-9P
714223-06-0P 714223-07-1P 714223-08-2P
714223-09-3P 714223-10-6P 714223-11-7P
714223-12-8P 714223-13-9P 714223-14-0P
714223-15-1P 714223-16-2P 714223-17-3P
714223-18-4P 714223-19-5P 714223-20-8P
714223-21-9P 714223-22-0P 714223-23-1P
714223-24-2P 714223-25-3P 714223-60-6P
714223-61-7P 714223-63-9P 714223-64-0P
714223-72-0P 714223-73-1P 714223-74-2P
714223-75-3P 714223-76-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(VR1 inhibitor; preparation of (quinazolin-4-yl)amines as VR1 inhibitors for treatment of pain and other VR1-mediated conditions)
RN 573688-59-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 573688-81-0 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-83-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 573688-84-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 573688-88-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-methanamine, N,N-bis(2-methoxyethyl)-7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-89-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-methanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-76-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[(1-ethyl-2-pyrrolidinyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-78-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(1-pyrrolidinyl)propyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-80-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(4-methyl-1-piperazinyl)propyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-82-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(dimethylamino)-2,2-dimethylpropyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-84-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(dimethylamino)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-86-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(dimethylamino)propyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 714222-88-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(1-pyrrolidinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-89-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(diethylamino)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-90-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(1-piperidinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-91-0 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-92-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(diethylamino)propyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-93-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(4-morpholinyl)ethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-94-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[3-(4-morpholinyl)propyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714222-95-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[2-(dimethylamino)-1-methylethyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-96-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 714222-97-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[4-(diethylamino)-1-methylbutyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-98-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(1,2,2,6,6-pentamethyl-4-piperidinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714222-99-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(1-methyl-4-piperidinyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-00-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-methyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-01-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-ethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-04-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(cyclopropylmethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-05-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(2-ethoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-02-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-03-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-propyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 714223-06-0 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-07-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(3-methoxypropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-08-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-[(tetrahydro-2-furanyl)methyl]-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-09-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(2,2-dimethylpropyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-10-6 HCAPLUS
CN Pyrrolidine, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-11-7 HCAPLUS
CN Piperidine, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-12-8 HCAPLUS
CN Morpholine, 4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-13-9 HCAPLUS
CN Piperidine, 4-methyl-1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-14-0 HCAPLUS
CN Thiomorpholine, 4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 714223-15-1 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-methyl-N-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-16-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N,N-di-2-propenyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-17-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N,N-dipropyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-18-4 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N,N-dimethyl-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-19-5 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(3,3-dimethylcyclohexyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-20-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 714223-21-9 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-carboxamide, N-(3,5-dimethylcyclohexyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-22-0 HCAPLUS
CN Piperazine, 1-(1-methylethyl)-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-23-1 HCAPLUS
CN Piperazine, 1-methyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-24-2 HCAPLUS
CN Piperazine, 1-cyclopentyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-25-3 HCAPLUS
CN Piperazine, 1-cycloheptyl-4-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-60-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 714223-61-7 HCAPLUS
CN L-Proline, 1-[[4-[[4-(1,1-dimethylethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-72-0 HCAPLUS
CN Glycine, N-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-73-1 HCAPLUS
CN β-Alanine, N-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-74-2 HCAPLUS

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 714223-63-9 HCAPLUS
CN L-Proline, 1-[[7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 714223-64-0 HCAPLUS
CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Butanoic acid, 4-[[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 714223-75-3 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)



RN 714223-76-4 HCAPLUS
CN L-Proline, 1-[[4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]pyrido[2,3-d]pyrimidin-2-yl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:591156 HCAPLUS
DOCUMENT NUMBER: 139:149640
TITLE: Preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for relieving pain
INVENTOR(S): Bakthavatchatam, Rajagopal; Blum, Charles A.; Brielmann, Harry L.; Caldwell, Timothy M.; De Lombaert, Stephane
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 294 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062209	A2	20030731	WO 2003-US1563	20030117
WO 2003062209	A3	20030904		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2473796	AA	20030731	CA 2003-2473796	20030117
BR 2003006982	A	20041026	BR 2003-6982	20030117
EP 1471910	A2	20041103	EP 2003-703887	20030117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005526714	T2	20050908	JP 2003-562090	20030117
US 2004106616	A1	20040603	US 2003-347210	20030121
ZA 2004005641	A	20050715	ZA 2004-5641	20040715
NO 2004003411	A	20040924	NO 2004-3411	20040816

PRIORITY APPLN. INFO.: US 2002-349920P P 20020117
US 2002-350527P P 20020122
WO 2003-US1563 W 20030117

OTHER SOURCE(S): MARPAT 139:149640
GI



I

AB Substituted quinazolin-4-ylamine analogs (shown as I; variables defined

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

below; e.g. (4-trifluoromethylphenyl)[7-(2-trifluoromethylphenyl)quinazolin-4-yl]amine) are provided. Such compds. are ligands that may be used to modulate VR1 capsaicin receptor activity in vivo or in vitro (no data), and are particularly useful in the treatment of conditions assocd. with pathol. receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compns. and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies. For I; V, X, W, Y and Z are each independently N or CR1, with the proviso that at least one of V and X is N; U is N or CR2, with the proviso that if V and X are N, then U is CR2; R1 = H, halogen, hydroxy, amino, C1-C8 alkyl, haloC1-C8alkyl, C1-C8alkoxy, haloC1-C8alkoxy and mono- and di(C1-C8alkyl)amino. R2 = (i) H, halogen, cyano, or -COOH; (ii) C1-C8alkanoyl, C2-C8alkanone, or C1-C8carbamate, each of which is (un)substituted with 1-9 substituents = Rb, or (iii) -Rc-M-A-Ry, wherein: Rc is CO-C3alkyl; M is a bond, N(Rz), O, S, SO2, (C:O)pN(Rz), N(Rz)(C:O)p, SO2N(Rz), or N(Rz)SO2, wherein p is 0 or 1; A is a bond or C1-C8alkyl, (un)substituted with 1-3 Rb. Ry and Rz, if present, are: (a) independently H, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C6-C10arylC1-C8alkyl, C2-C8alkyl ether, C1-C8alkoxy, a 4- to 10-membered carbocycle or heterocycle, or joined to R1 to form a 4- to 10-membered carbocycle or heterocycle, wherein each Ry and Rz = (un)substituted with 1-9 Rb; or (b) joined to form a 4- to 10-membered carbocycle or heterocycle that is (un)substituted with 1-9 Rb; Ar2 is a 5- to 7-membered arom. heterocycle, (un)substituted with 1-3 LRa. Ar1 is a 5- to 10-membered arom. carbocycle or heterocycle, (un)substituted with 1-3 LRa; L = bond, -O-, -C(O)-, -OC(O)-, -C(O)O-, -O-C(O)O-, -S(O)m-, -NRx-, -C(O)NHRx-, -NHRxC(O)-, -NRxS(O)m-, -S(O)mNRx- and -N[S(O)mRx]S(O)m-; wherein m = 0, 1 and 2; and Rx = H and C1-C8alkyl; Ra = (i) H, halogen, cyano and nitro; and (ii) C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, C2-C8alkyl ether, 3- to 10-membered heterocycles, mono- and di(C1-C8alkyl)amino and (3- to 10-membered heterocycle)C1-C6 alkyl, each of which is (un)substituted with 1-9 Rb. Rb = hydroxy, halogen, amino, aminocarbonyl, amido, cyano, nitro, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylthio, C1-C8alkyl ether, hydroxyC1-C8alkyl, haloC1-C8alkyl, Ph, phenyl(C1-C8alkyl), mono and di(C1-C6 alkyl)amino, (SO2)C1-C8alkyl, 5- to 7-membered heterocycle and (5- to 7-membered heterocycle)(C1-C8alkyl). Although the methods of prepn. are not claimed, many example prepns. and characterization data for >500 examples of I are included.

IT **573688-59-2P**, (4-tert-Butylphenyl)[2-[(cis-2,6-dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl]amine **573688-79-6P**, [2-[(2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **573688-81-0P**, [2-[(cis-2,6-Dimethylmorpholin-4-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **573688-83-2P**, [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **573688-84-3P**, [2-[(3,3-Dimethylpiperidin-1-yl)methyl]-7-(3-trifluoromethylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **573688-88-7P**, [2-[[Bis(2-methoxyethyl)amino]methyl]-7-(3-methylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine **573688-89-8P**, [2-[[Bis(2-methoxyethyl)amino]methyl]-7-(3-trifluoromethylpyridin-2-yl)pyrido[2,3-d]pyrimidin-4-yl](4-trifluoromethylphenyl)amine
RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate and receptor detector; preparation of substituted quinazolin-4-ylamine analogs as VR1 capsaicin receptor antagonists for

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

relieving pain and for detecting receptors)

RN 573688-59-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, N-[4-(1,1-dimethylethyl)phenyl]-2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 573688-79-6 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[(2,6-dimethyl-4-morpholinyl)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573688-81-0 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 573688-83-2 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-7-(3-methyl-2-pyridinyl)-N-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 573688-84-3 HCAPLUS
CN Pyrido[2,3-d]pyrimidin-4-amine, 2-[(3,3-dimethyl-1-piperidinyl)methyl]-N-[4-(trifluoromethyl)phenyl]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 573688-88-7 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-methanamine, N,N-bis(2-methoxyethyl)-7-(3-methyl-2-pyridinyl)-4-[[4-(trifluoromethyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 573688-89-8 HCAPLUS
CN Pyrido[2,3-d]pyrimidine-2-methanamine, N,N-bis(2-methoxyethyl)-4-[[4-(trifluoromethyl)phenyl]amino]-7-[3-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)